Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 29, 2026
11 tracked managers disclosed the same change for Q1 2026. From a 13F filed May 29, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
Reduced
Compared with the manager's Q4 2025 13F
315,541
280,541
−11.1%
Share count drives classification; reported value also moves with price
0.65%
Within the filing's reported positions, not the manager's total assets
11
For Q1 2026
Jason K Garland (CFO) sold ~$106K of Repligen
Planned saleFederal contracts
Xcell lab controllers and accessories
The Department of Health and Human Services has committed $175K to Repligen so far. It runs until Sep 30, 2026.
Fund moves
16 tracked managers disclosed the same change for Q1 2026. From a 13F filed May 22, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
